Detect in utero exposure to cannabis (marijuana) in neonates, consistent with maternal use during approximately the last trimester of pregnancy.
- Patient Preparation
- Umbilical Cord (At least 8 inches, approximately the width of a sheet of paper.)
- Specimen Preparation
- Drain and discard any blood. Rinse the exterior of the cord segment with normal saline or water. Pat the cord dry and transport at least 8 inches of umbilical cord in a routine urine collection cup or Security Kit for Meconium/Umbilical Drug Detection (ARUP supply #51548) available online through eSupply using ARUP Connect™ or by contacting ARUP Client Services at (800) 522-2787. (Min: 6 inches)
- Storage/Transport Temperature
- Unacceptable Conditions
- Cords soaking in blood or other fluid. Formalin fixed. Tissue that is obviously decomposed.
- Ambient: 1 week; Refrigerated: 3 weeks; Frozen: 1 year
|Drugs/Drug Classes||Cutoff Concentrations (ng/g)|
This test is designed to detect and document exposure that occurred during approximately the last trimester of a full term pregnancy, to a common cannabis (marijuana) metabolite. Alternative testing is available to detect other drug exposures. The pattern and frequency of drug(s) used by the mother cannot be determined by this test. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drugs in umbilical cord tissue depends on extent of maternal drug use, as well as drug stability, unique characteristics of drug deposition in umbilical cord tissue, and the performance of the analytical method. Drugs administered during labor and delivery may be detected. Detection of drugs in umbilical cord tissue does not insinuate impairment and may not affect outcomes for the infant. Interpretive questions should be directed to the laboratory.
|Component Test Code*||Component Chart Name||LOINC|
|3000257||THC-COOH, Cord, Qual||61063-4|